US Patent 9,833,419 Estradiol Monolithic Transdermal System: Claim Scope, Coverage Map, and US Patent Landscape
US Patent 9,833,419 is directed to a monolithic estradiol transdermal drug delivery system built around a single adhesive polymer matrix layer (with estradiol as the only drug) engineered to hit a defined coat-weight and estradiol-flux window. The key exclusivity drivers in the claims are (i) the structural architecture “monolithic” with one adhesive matrix layer, (ii) drug loading and coat weight thresholds, and (iii) a quantified flux range. Dependent claims narrow composition to specific adhesive blends (acrylic + silicone + soluble PVP), defined adhesive ratios, and specified penetration enhancers (oleyl alcohol, dipropylene glycol, or both), plus specific residence durations and discrete day-dose targets.
What is the exact claim scope of US Patent 9,833,419 for estradiol transdermal patches?
Core invention (Claim 1) in enforceable terms
Claim 1 requires all of the following to be present in the accused product:
-
Device architecture
- Monolithic transdermal drug delivery system
- Has:
- (i) a backing layer
- (ii) a single adhesive polymer matrix layer defining an active surface area
- (iii) optionally, a release liner
-
Single-drug constraint
- The adhesive polymer matrix layer comprises an adhesive polymer matrix comprising estradiol as the only drug.
-
Quantitative coat-weight threshold
- Adhesive polymer matrix layer coat weight > 10 mg/cm².
-
Quantitative drug-loading threshold
- Contains > 0.156 mg/cm² estradiol, based on the active surface area basis in the claim.
-
Quantified performance/flux window
- Achieves estradiol flux from 0.0125 to about 0.05 mg/cm²/day, based on active surface area.
Practical reading
- Claim 1 is not limited to a particular adhesive type. It is limited by measurable thresholds (coat weight, estradiol loading density, and flux).
- It is also limited by the single-matrix, estradiol-only premise. If a product has additional drugs in the adhesive matrix (or another active compound resident in the adhesive layer) that can create a design-around.
How do dependent claims narrow composition and performance in US 9,833,419?
Claim 2: Adhesive polymer matrix composition family
- Requires the adhesive polymer matrix comprises:
- an acrylic adhesive
- a silicone adhesive
- soluble PVP
Claim 3: Quantitative composition ranges (composition-of-matrix)
Requires the adhesive polymer matrix (dry weight basis) contains approximately:
- 2–25% by weight acrylic adhesive
- 45–70% by weight silicone adhesive
- 2–25% by weight soluble PVP
- 5–15% penetration enhancer
- 0.1–10% by weight estradiol
All based on total dry weight of adhesive polymer matrix.
Claim 4–6: Penetration enhancer specificity
- Claim 4: penetration enhancer comprises oleyl alcohol
- Claim 5: penetration enhancer comprises dipropylene glycol
- Claim 6: penetration enhancer comprises oleyl alcohol and dipropylene glycol
Claim 7: Adhesive blend ratio constraint
- Acrylic adhesive : silicone adhesive is about 1:2 to about 1:6, based on total weight of the acrylic and silicone adhesives.
This is a derived constraint that interacts with Claim 3’s broader weight % ranges.
Claim 8: Treatment duration selection
- Estradiol amount effective to deliver therapeutically effective amount over periods selected from:
- at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days
This looks like a usability/performance limitation tied to patch design and/or release duration.
Claim 9: Discrete daily dose targets
- Estradiol amount delivers amount selected from:
- about 0.025, 0.0375, 0.05, 0.075, 0.1 mg/day
This is a dose-selection narrowing tied to release.
Claims 10–14: Discrete flux value assertions
Claim 1’s flux range is concretized into specific flux embodiments:
- Claim 10: 0.0125 mg/cm²/day
- Claim 11: 0.0133 mg/cm²/day
- Claim 12: about 0.015 mg/cm²/day
- Claim 13: about 0.0167 mg/cm²/day
- Claim 14: about 0.0175 mg/cm²/day
Claim 15: Specific estradiol % embodiment
- Adhesive polymer matrix comprises about 1.6% by weight estradiol (dry weight basis).
Which technical variables drive infringement risk for US 9,833,419 (flux vs loading vs coat weight)?
Infringement is most sensitive to Claim 1’s quantifiable boundaries
- Coat weight: must be > 10 mg/cm²
- Estradiol loading density: must be > 0.156 mg/cm²
- Flux: must be within 0.0125 to about 0.05 mg/cm²/day
Lower risk pathways if designing around
- Miss coat-weight threshold (≤ 10 mg/cm²)
- Miss drug loading threshold (≤ 0.156 mg/cm²)
- Engineer flux outside the range (< 0.0125 or > 0.05 mg/cm²/day)
- Break “estradiol only drug” by including additional active agents in the adhesive matrix
- Break monolithic “single adhesive polymer matrix layer” by using multilayer adhesive structures where estradiol is not distributed in a single adhesive polymer matrix layer as claimed
Composition narrowing makes some competitors easier to clear
Dependent claims 2–7 narrow to particular matrix families and specific penetration enhancers. If a competitor uses different penetration enhancers, the dependent claims may fall away, leaving Claim 1 as the main risk unless Claim 1 structural/performance requirements are also met.
What formulations are protected: acrylic/silicone/PVP matrices with oleyl alcohol and dipropylene glycol?
Protected formulation core (from dependent claim set)
- Adhesive matrix: acrylic + silicone adhesives blended with soluble PVP
- Penetration enhancer:
- oleyl alcohol
- dipropylene glycol
- or both
- Estradiol is included within the adhesive polymer matrix (estradiol-only active constraint).
Protected ranges (Claim 3)
- Acrylic adhesive: 2–25 wt%
- Silicone adhesive: 45–70 wt%
- Soluble PVP: 2–25 wt%
- Penetration enhancer: 5–15 wt%
- Estradiol: 0.1–10 wt%
Protected ratio (Claim 7)
- Acrylic:silicone 1:2 to 1:6
Protected specific embodiment (Claim 15)
- Estradiol ~1.6 wt% (dry adhesive matrix basis)
What is not explicitly required
- Specific drug reservoir layers, membranes, or rate-controlling structures are not claimed as necessary in Claim 1.
- The claim centers on a monolithic adhesive matrix architecture plus measurable flux outcomes.
When does exclusivity expire for US 9,833,419 and how does the patent term interact with generic risk?
This analysis cannot produce an accurate “loss of exclusivity” timeline without the following: the patent’s filing date, priority data, prosecution history, and any PTA/terminal disclaimer terms, plus relevant FDA exclusivity coverage for the specific estradiol product(s) implicated. The provided record contains only the claim text.
No timeline is generated.
How strong is the patent estate around US 9,833,419: claim breadth and likely design-around space?
Strength indicators
- Claim 1 is quantitatively defined by coat weight, drug loading density, and flux window. Quantitative ranges often improve enforceability because infringement testing can map to defined targets.
- The claim includes both:
- composition/structure constraints (single monolithic adhesive matrix; estradiol as only drug in that matrix), and
- performance constraints (flux window).
Breadth indicators
- Claim 1 does not require acrylic vs silicone vs PVP. That expands coverage beyond dependent formulations, as long as the product meets thresholds and architecture.
- Dependent claims add composition narrowness but also provide multiple fall-through hooks for different accused formulations (oleyl alcohol vs dipropylene glycol vs both).
Design-around space
- The most straightforward path is to engineer flux outside the specified range or adjust coat weight / loading density.
- Another path is structural: using a different adhesive architecture so that the “single adhesive polymer matrix layer” condition is not met.
- Another path is active composition: adding another drug to the adhesive matrix would defeat “estradiol as the only drug” in the matrix.
What other US patents commonly cluster with estradiol monolithic adhesive matrix claims?
This cannot be completed accurately without an Orange Book / USPTO family search for the specific application(s) that led to US 9,833,419 and the estradiol products that map to its claims. The prompt does not include:
- the patent number’s bibliographic data (assignee, application number, filing/priority dates),
- citation list,
- related family members,
- or the FDA NDA/ANDA/505(b)(2) references.
No additional patent landscape is produced.
What generic entry risks exist for estradiol transdermal systems that may fall within the flux window?
If an ANDA/505(b)(2) candidate matches the claim fundamentals
- It is at meaningful risk if the generic:
- has a monolithic transdermal structure with a single adhesive polymer matrix layer,
- uses estradiol as the only drug in that adhesive matrix,
- hits coat weight >10 mg/cm²,
- hits estradiol loading density >0.156 mg/cm², and
- achieves estradiol flux 0.0125 to about 0.05 mg/cm²/day based on active surface area.
If a candidate misses even one primary boundary
- Risk drops substantially for Claim 1.
- It may remain exposed to dependent claims if it shares the specific adhesive blend and penetration enhancer system, but Claim 1 is the gatekeeper.
How does US 9,833,419 compare with typical estradiol patch patent strategies (membranes vs matrix systems)?
Claim 1 is a matrix-system patent
Many estradiol patch concepts in the market use:
- multilayer systems (drug reservoir layer + rate-controlling membrane) or
- adhesive matrix variants with different rate-control mechanisms.
US 9,833,419 is aligned to a monolithic adhesive matrix approach, and it uses quantifiable thresholds rather than requiring a named membrane type. That makes the claim more compatible with competitors that also pursue matrix systems, and less compatible with devices that rely on a membrane/reservoir architecture that prevents a finding that the product has “a single adhesive polymer matrix layer” with estradiol as the only drug in that layer.
Key Takeaways
- US 9,833,419 Claim 1 covers a monolithic estradiol transdermal patch with a single adhesive polymer matrix layer, estradiol as the only drug in that matrix, coat weight >10 mg/cm², estradiol loading >0.156 mg/cm², and estradiol flux 0.0125 to ~0.05 mg/cm²/day.
- Dependent claims tighten to acrylic + silicone + soluble PVP matrices, and to oleyl alcohol and/or dipropylene glycol as penetration enhancers, with defined wt% ranges and an acrylic:silicone ratio of ~1:2 to ~1:6.
- Infringement analysis is dominated by measurable boundaries (coat weight, loading density, and flux). Passing even one boundary below/above the claim window is a likely design-around.
- A complete “patent landscape,” “Orange Book status,” and “exclusivity expiration” timeline cannot be produced from the provided information.
FAQs
- What lab tests map to the Claim 1 “estradiol flux” requirement (mg/cm²/day)?
- If a patch uses the same adhesives but includes a different penetration enhancer, which claims in US 9,833,419 are most vulnerable?
- How does “estradiol as the only drug” in the adhesive polymer matrix affect combination patches?
- Can an estradiol patch with ≤10 mg/cm² coat weight avoid Claim 1 exposure even if flux is within 0.0125 to ~0.05 mg/cm²/day?
- Which flux subranges (0.0125, 0.0133, 0.015, 0.0167, 0.0175 mg/cm²/day) are most likely to be asserted in litigation strategy?
References (APA)
- United States Patent 9,833,419.
